Volume 106, Issue s178 pp. 15-18

Cognitive decline and treatment options for patients with vascular dementia

T. Erkinjuntti,

T. Erkinjuntti

Department of Clinical Neurology, Helsinki University Central Hospital, Helsinki, Finland

Search for more papers by this author

T. Erkinjuntti,

T. Erkinjuntti

Department of Clinical Neurology, Helsinki University Central Hospital, Helsinki, Finland

Search for more papers by this author

First published: 18 December 2002

https://doi.org/10.1034/j.1600-0404.106.s178.4.x

Citations: 10

Timo Erkinjuntti, MD, PhD, Chief, Memory Research Unit, Department of Clinical Neurology, Helsinki University Central Hospital, PL 300, 00029 HVS, Finland
Tel.: +3589 4717 2353
Fax: +3589 4717 2352
e-mail: [email protected]

Share a link

Email
Wechat
Bluesky

Abstract

Cognitive impairment is the primary symptom of vascular dementia (VaD). Animal and human studies indicate that, as with Alzheimer's disease (AD), deficits in cholinergic transmission − including nicotinic receptor binding abnormalities − may be responsible for the development of cognitive impairment associated with VaD. Therefore, studies of acetylcholinesterase inhibitors (AChEIs) have been initiated and have shown promising results to date. These agents have demonstrated cognitive and global benefits in patients with VaD. Additionally, functional and behavioral benefits have been reported with the dual-mechanism AChEI galantamine. These studies suggest a potential role for AChEIs in the management of cognitive impairment associated with VaD.

References

1 Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl^™). Int J Clin Pract Suppl 2001; 120(Suppl.): 24–8.
CAS PubMed Web of Science® Google Scholar
2 Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS–AIREN International Workshop. Neurology 1993; 43: 250–60.
10.1212/WNL.43.2.250
CAS PubMed Web of Science® Google Scholar
3 Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473–80.
10.1212/WNL.42.3.473
CAS PubMed Web of Science® Google Scholar
4 Wentzel C, Rockwood K, MacKnight C et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology 2001; 57: 714–6.
10.1212/WNL.57.4.714
CAS PubMed Web of Science® Google Scholar
5 Swan GE, Decarli C, Miller BL et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology 1998; 51: 986–93.
10.1212/WNL.51.4.986
CAS PubMed Web of Science® Google Scholar
6 Fischer P, Gatterer G, Marterer A, Simanyi M, Danielczyk W. Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct dementia. Acta Psychiatr Scand 1990; 81: 551–3.
10.1111/j.1600-0447.1990.tb05497.x
PubMed Web of Science® Google Scholar
7 Ballard C, O'Brien J, Morris CM et al. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: 499–503.
10.1002/gps.381
CAS PubMed Web of Science® Google Scholar
8 Erkinjuntti T. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs 1999; 12: 35–48.
10.2165/00023210-199912010-00004
Web of Science® Google Scholar
9 Rockwood K, Ebly E, Hachinski V, Hogan D. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 1997; 54: 33–9.
10.1001/archneur.1997.00550130019010
PubMed Web of Science® Google Scholar
10 Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51.
10.1016/S0140-6736(98)03086-4
CAS PubMed Web of Science® Google Scholar
11 Dib M. Methodological issues and therapeutic perspectives in vascular dementia: a review. Arch Gerontol Geriatr 2001; 33: 71–80.
10.1016/S0167-4943(01)00110-8
PubMed Web of Science® Google Scholar
12 Togashi H, Matsumoto M, Yoshioka M, Hirokami M, Minami M, Saito H. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117–20.
10.1016/0304-3940(94)90854-0
CAS PubMed Web of Science® Google Scholar
13 Kimura S, Saito H, Minami M et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167–78.
10.1016/S0300-483X(00)00312-7
CAS PubMed Web of Science® Google Scholar
14 Saito H, Togashi H, Yoshioka M, Nakamura N, Minami M, Parvez H. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 1: S257–S259.
10.1111/j.1440-1681.1995.tb02906.x
CAS Google Scholar
15 Togashi H, Kimura S, Matsumoto M, Yoshioka M, Minami M, Saito H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996; 27: 520–5.
10.1161/01.STR.27.3.520
PubMed Web of Science® Google Scholar
16 Ferrari R, Frasoldati A, Leo G et al. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci Lett 1999; 277: 169–72.
10.1016/S0304-3940(99)00879-4
CAS PubMed Web of Science® Google Scholar
17 Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000; 393: 165–70.
10.1016/S0014-2999(00)00093-5
CAS PubMed Web of Science® Google Scholar
18 Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994; 5: 163–7.
10.1159/000106715
CAS PubMed Web of Science® Google Scholar
19 Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103: 1211–20.
10.1007/BF01271206
CAS PubMed Web of Science® Google Scholar
20 Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159–69.
10.1046/j.1468-1331.2000.00046.x
CAS PubMed Web of Science® Google Scholar
21 Mendez MF, Younesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999; 11: 268–70.
10.1176/jnp.11.2.268
CAS PubMed Web of Science® Google Scholar
22 Pratt R. Results of clinical studies with donepezil in VAD [Abstract]. 2nd International Congress on Vascular Dementia, Pathos, Cyprus, 47 October 2001.
Google Scholar
23 Frolich L, Klinger T, Berger FM. Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease [Abstract]. 2nd International Congress on Vascular Dementia, Pathos, Cyprus, 47 October 2001.
Google Scholar
24 Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CRV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–90.
10.1016/S0140-6736(02)08267-3
PubMed Web of Science® Google Scholar
25 Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15(Suppl. 1): S19–S25.
10.1097/00002093-200108001-00004
CAS PubMed Web of Science® Google Scholar
26 Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD. a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261–8.
10.1212/WNL.54.12.2261
CAS PubMed Web of Science® Google Scholar
27 Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76.
10.1212/WNL.54.12.2269
CAS PubMed Web of Science® Google Scholar
28 Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445–9.
10.1136/bmj.321.7274.1445
CAS PubMed Google Scholar

Citing Literature

All articles

Cognitive decline and treatment options for patients with vascular dementia

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Cognitive decline and treatment options for patients with vascular dementia

Abstract

References

Citing Literature

References

Related

Information